12:00 AM
Oct 06, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

VGX-1027: Phase I data

A placebo-controlled, single ascending-dose U.S. Phase I trial in 54 healthy volunteers showed that VGX-1027 was well tolerated.

Read the full 75 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >